October 5, 2012Current Opinion in Lipidology
Emerging therapeutic agents to lower lipoprotein (a) levels
Key result
Specific apolipoprotein (a) inhibitors reduce apo(a) mRNA and protein levels by up to 86% without significantly affecting other lipoproteins.
Why the study?
Do emerging therapeutic agents effectively lower lipoprotein (a) levels?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Rationale for cardiovascular outcomes trials of apo(a) inhibitors; leaves open whether Lp(a) reduction improves prognosis.
Structured PICO
Do emerging therapeutic agents effectively lower lipoprotein (a) levels?
I
Intervention
Emerging therapeutic agents to lower Lp(a), including apheresis, antisense oligonucleotides to apoB, PCSK9 monoclonal antibodies, CETP inhibitors, thyromimetics, and specific apolipoprotein (a) inhibitors
O
Outcome
Lipoprotein (a) [Lp(a)] loweringsurrogate
Emerging therapies, particularly specific apo(a) inhibitors, show promise in significantly lowering Lp(a) levels, providing a rationale to test if this reduction translates to decreased cardiovascular events.
Cite This Study
Kolski et al. (2012) conducted a review in Elevated Lipoprotein (a) / Cardiovascular disease. Emerging therapeutic agents (e.g., specific apolipoprotein (a) inhibitors) was evaluated on Lipoprotein (a) levels. Specific apolipoprotein (a) inhibitors reduce apo(a) mRNA and protein levels by up to 86% without significantly affecting other lipoproteins.